Abstract: Migraine is a common neurological disease and one of the most disabling diseases in the world. It brings enormous economic and social burdens to patients, impairs their physical and mental health, and affects their quality of life. Currently, the treatment options for migraines mainly include acute and preventive treatments. With the exploration of signal molecules related to migraines, more and more treatments have been developed. As a new emerging treatment for migraines, calcitonin gene-related peptide(CGRP) receptor antagonists have attracted much attention. This article reviews the pathogenesis of migraines mediated by CGRP and the research advances in CGRPtargeted drugs, aiming to provide some reference for the development of migraine drugs.